Loading...
Please wait, while we are loading the content...
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
| Content Provider | Scilit |
|---|---|
| Author | Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan |
| Copyright Year | 2015 |
| Description | Key Points The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions. |
| Related Links | http://www.bloodjournal.org/content/bloodjournal/126/13/1551.full.pdf |
| Ending Page | 1554 |
| Page Count | 4 |
| Starting Page | 1551 |
| DOI | 10.1182/blood-2015-03-635235 |
| Journal | Blood |
| Issue Number | 13 |
| Volume Number | 126 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2015-09-24 |
| Access Restriction | Open |
| Subject Keyword | Hematology Myelofibrosis Allele Burden C.1849g Jak2p.v617f Allele Ruxolitinib Treatment Journal: Blood (Vol- 123, Issue- 13) |
| Content Type | Text |
| Resource Type | Article |